var data={"title":"Chloramphenicol: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Chloramphenicol: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5867?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=chloramphenicol-patient-drug-information\" class=\"drug drug_patient\">see &quot;Chloramphenicol: Patient drug information&quot;</a> and <a href=\"topic.htm?path=chloramphenicol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Chloramphenicol: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708673\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Blood dyscrasias: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) are known to occur after the administration of chloramphenicol. In addition, there have been reports of aplastic anemia attributed to chloramphenicol which later terminated in leukemia. Blood dyscrasias have occurred after both short-term and prolonged therapy with this drug. Chloramphenicol must not be used when less potentially dangerous agents will be effective. It must not be used in the treatment of trivial infections or where it is not indicated, as in colds, influenza, infections of the throat; or as a prophylactic agent to prevent bacterial infections.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">It is essential that adequate blood studies be made during treatment with the drug. While blood studies may detect early peripheral blood changes, such as leukopenia, reticulocytopenia, or granulocytopenia, before they become irreversible, such studies cannot be relied on to detect bone marrow depression prior to development of aplastic anemia. To facilitate appropriate studies and observation during therapy, it is desirable that patients be hospitalized.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149436\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Chloromycetin;</li>\n      <li>Chloromycetin Succinate;</li>\n      <li>Diochloram;</li>\n      <li>Pentamycetin</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149484\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antibiotic, Miscellaneous</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149440\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Serious infections:</b> IV: 50 to 100 mg/kg/day in divided doses every 6 hours; maximum daily dose: 4 g/day (Moffa 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149462\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=chloramphenicol-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Chloramphenicol: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Serious infections:</b> Infants, Children, and Adolescents: IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Manufacturer&rsquo;s labeling:</i> 50 mg/kg/day in divided doses every 6 hours; severe infections (eg, bacteremia, meningitis) may require up to 100 mg/kg/day; decrease to 50 mg/kg/day as soon as possible. <b>Note:</b> In infants and children with suspected immature metabolic function, dose may be initiated at 25 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Alternative dosing:</i> 50 to 100 mg/kg/day in divided doses every 6 hours; maximum daily dose: 4 g/day (R<i>ed Book</i> [AAP] 2015)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149441\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149442\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment may be necessary. Use with caution; monitor serum concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149443\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no specific dosage adjustments provided in the manufacturer's labeling; however, dosage adjustments may be necessary. Use with caution; monitor serum concentrations.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149410\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 1 g (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149395\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149415\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: For IV use only; do not administer IM. Can be administered IVP over at least 1 minute at a concentration of 100 mg/mL.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49130927\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 2]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). Assess risk to determine appropriate containment strategy (USP-NF 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149414\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Serious infections:</b> Treatment of serious infections, including cystic fibrosis exacerbations, bacterial meningitis, and bacteremia, caused by <i>Chlamydiaceae</i>, <i>Haemophilus influenzae</i>, <i>Rickettsia</i>, <i>Salmonella</i> spp. (acute infections), and other organisms when other less toxic agents are ineffective or contraindicated.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Guideline recommendations: </i></b>Chloramphenicol may be considered for use as an alternative agent to doxycycline in the treatment of tickborne rickettsial diseases (eg, Rocky Mountain spotted fever [RMSF]); however, epidemiologic studies suggest that chloramphenicol-treated patients with RMSF are at a higher risk of death compared to tetracycline-treated patients. In addition, chloramphenicol is <i>not</i> effective in the treatment of human ehrlichiosis or anaplasmosis, therefore, use with caution in the <i>empiric</i> treatment of tickborne rickettsial diseases (CDC [Biggs 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149491\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Chloromycetin may be confused with chlorambucil, Chlor-Trimeton</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149402\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Central nervous system: Confusion, delirium, depression, headache</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Dermatologic: Skin rash, urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Gastrointestinal: Diarrhea, enterocolitis, glossitis, nausea, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hematologic &amp; oncologic: Aplastic anemia, bone marrow depression, granulocytopenia, hypoplastic anemia, pancytopenia, thrombocytopenia </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Hypersensitivity: Anaphylaxis, angioedema, hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Ophthalmic: Optic neuritis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Miscellaneous: Drug toxicity (Gray syndrome), fever</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149418\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to chloramphenicol or any component of the formulation; treatment of trivial or viral infections; bacterial prophylaxis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149399\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Blood dyscrasias: <b>[US Boxed Warning]: Serious and fatal blood dyscrasias (aplastic anemia, hypoplastic anemia, thrombocytopenia, and granulocytopenia) have occurred after both short-term and prolonged therapy; do not use for minor infections or when less potentially toxic agents are effective. Monitor CBC frequently in all patients;</b> discontinue if evidence of myelosuppression. Irreversible bone marrow suppression may occur weeks or months after therapy. Avoid prolonged or repeated courses of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gray syndrome: Characterized by cyanosis, abdominal distention, vasomotor collapse (often with irregular respiration), and death. Reaction appears to be associated with serum levels &ge;50 mcg/mL (Powell 1982).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Superinfection: Prolonged use may result in fungal or bacterial superinfection, including <i>C. difficile</i>-associated diarrhea (CDAD) and pseudomembranous colitis; CDAD has been observed &gt;2 months postantibiotic treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: Use with caution; reduced dosage and serum concentration monitoring is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution; reduced dosage and serum concentration monitoring is recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Glucose 6-phosphate dehydrogenase deficiency: Use with caution in patients with glucose 6-phosphate dehydrogenase deficiency.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Neonates: Use in premature and full-term neonates and infants has resulted in &ldquo;gray syndrome&quot; characterized by cyanosis, abdominal distention (with or without emesis), vasomotor collapse (often with irregular respiration), and death; progression of symptoms is rapid; prompt termination of therapy required. Reaction may result from drug accumulation caused by immature hepatic or renal function in neonates and infants.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149480\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Inhibits</b> CYP2C9 (weak)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149404\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=9241&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alcohol (Ethyl): Chloramphenicol (Systemic) may enhance the adverse/toxic effect of Alcohol (Ethyl). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: Chloramphenicol (Systemic) may decrease the metabolism of Barbiturates. Barbiturates may increase the metabolism of Chloramphenicol (Systemic). <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Antibiotics may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG Vaccine (Immunization): Antibiotics may diminish the therapeutic effect of BCG Vaccine (Immunization). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Carbocisteine: Chloramphenicol (Systemic) may enhance the adverse/toxic effect of Carbocisteine. Specifically, chloramphenicol may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CefTAZidime: Chloramphenicol (Systemic) may diminish the therapeutic effect of CefTAZidime.  Management: Consider using a different combination of antimicrobials, especially if bactericidal activity is desired. If these agents are combined, monitor for reduced antimicrobial effectiveness and/or therapeutic failure.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cholera Vaccine: Antibiotics may diminish the therapeutic effect of Cholera Vaccine. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Chloramphenicol (Systemic) may increase the serum concentration of CycloSPORINE (Systemic).  Management: Cyclosporine dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor cyclosporine concentrations and response closely following initiation and/or discontinuation of chloramphenicol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fosphenytoin: May decrease the serum concentration of Chloramphenicol (Systemic). Fosphenytoin may increase the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of Fosphenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lactobacillus and Estriol: Antibiotics may diminish the therapeutic effect of Lactobacillus and Estriol. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phenytoin: May decrease the serum concentration of Chloramphenicol (Systemic). Phenytoin may increase the serum concentration of Chloramphenicol (Systemic). Chloramphenicol (Systemic) may increase the serum concentration of Phenytoin.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">RifAMPin: May increase the metabolism of Chloramphenicol (Systemic).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Picosulfate: Antibiotics may diminish the therapeutic effect of Sodium Picosulfate.  Management: Consider using an alternative product for bowel cleansing prior to a colonoscopy in patients who have recently used or are concurrently using an antibiotic.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sulfonylureas: Chloramphenicol (Systemic) may decrease the metabolism of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Chloramphenicol (Systemic) may increase the serum concentration of Tacrolimus (Systemic).  Management: Tacrolimus dose reductions will likely be required with initiation of concurrent chloramphenicol.  Monitor tacrolimus concentrations and response closely following initiation and/or discontinuation of chloramphenicol.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Typhoid Vaccine: Antibiotics may diminish the therapeutic effect of Typhoid Vaccine. Only the live attenuated Ty21a strain is affected.  Management: Vaccination with live attenuated typhoid vaccine (Ty21a) should be avoided in patients being treated with systemic antibacterial agents.  Use of this vaccine should be postponed until at least 3 days after cessation of antibacterial agents.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin B12: Chloramphenicol (Systemic) may diminish the therapeutic effect of Vitamin B12. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vitamin K Antagonists (eg, warfarin): Chloramphenicol (Systemic) may enhance the anticoagulant effect of Vitamin K Antagonists. Chloramphenicol (Systemic) may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Voriconazole: Chloramphenicol (Systemic) may increase the serum concentration of Voriconazole. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50102719\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">C (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149420\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Animal reproduction studies have not been conducted. Chloramphenicol crosses the placenta producing cord concentrations approaching maternal serum concentrations. An increased risk of teratogenic effects has not been associated with the use of chloramphenicol in pregnancy (Czeizel 2000; Heinonen 1977). &quot;Gray Syndrome&quot; has occurred in premature infants and newborns receiving chloramphenicol. Chloramphenicol may be used as an alternative agent for the treatment of Rocky Mountain spotted fever in pregnant women although caution should be used when administration occurs during the third trimester (CDC [Biggs 2016]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149421\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol and its inactive metabolites are present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:0em;\">Chloramphenicol is well absorbed following oral administration; however, metabolism and excretion are highly variable in infants and children. The half-life is also significantly prolonged in low birth weight infants (Powell 1982). Due to the potential for serious adverse reactions in the breastfed infant, the manufacturer recommends a decision be made to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother. Other sources recommended avoiding use while breast-feeding, especially young infants (&lt;34 weeks postconceptual age or &lt;1 month of age) or when unusually large doses are needed (Atkinson 1988; Matsuda 1984; Plomp 1983; WHO 2002). In general, antibiotics that are present in breast milk may cause non-dose-related modification of bowel flora. Infants exposed to chloramphenicol from breast milk should be monitored for GI disturbances, hemolysis and jaundice (WHO 2002).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149422\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">May have increased dietary need for riboflavin, pyridoxine, and vitamin B<sub>12</sub>. Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149408\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential (baseline and every 2 days during therapy), periodic hepatic and renal function tests, serum drug concentration</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149411\" class=\"block rer drugH1Div\"><span class=\"drugH1\">Reference Range</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Therapeutic levels:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Pediatric:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak: Neonates: 15 to 25 mcg/mL (Mulhall 1983); Infants, Children, and Adolescents: 15 to 30 mcg/mL (Balbi 2004; Coakley 1992; Long 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Trough: 5 to 15 mcg/mL</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adult:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peak: 10 to 20 mcg/mL (Ambrose 1984; Hammet-Stabler 1998)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Trough: 5 to 10 mcg/mL (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Timing of serum samples: Draw levels 0.5 to 1.5 hours after completion of IV dose (Hammet-Stabler 1998)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149398\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Reversibly binds to 50S ribosomal subunits of susceptible organisms preventing amino acids from being transferred to growing peptide chains thus inhibiting protein synthesis</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F149417\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: To most tissues and body fluids (Ambrose 1984); good CSF and brain penetration</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF concentration with uninflamed meninges: 21% to 50% of plasma concentration </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">CSF concentration with inflamed meninges: 45% to 89% of plasma concentration </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol: V<sub>d</sub>: 0.6 to 1 L/kg (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol succinate: V<sub>d</sub>: 0.2 to 3.1 L/kg (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: Chloramphenicol: ~60%; decreased with hepatic or renal dysfunction and 30% to 40% in newborn infants (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol: Hepatic to metabolites (inactive) (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol succinate: Hydrolyzed in the liver, kidney, and lungs to chloramphenicol (active) (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Bioavailability:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol: Oral: ~80% (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Chloramphenicol succinate: IV: ~70%; highly variable, dependent upon rate and extent of metabolism to chloramphenicol (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Neonates: 1 to 2 days: 24 hours; 10 to 16 days: 10 hours</p>\n    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">Chloramphenicol: Infants: Significantly prolonged (Powell 1982); Children 4 to 6 hours; Adults: ~4 hours (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Hepatic disease: Prolonged (Ambrose 1984)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~30% as unchanged chloramphenicol succinate in adults, 6% to 80% in children; 5% to 15% as chloramphenicol) (Ambrose 1984; Powell 1982)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323057\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Chloramphenicol Sod Succinate Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">1 g (1): $46.70</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2869368\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abefen (MX);</li>\n      <li>Aglomycetin (IN);</li>\n      <li>Alfa Cloromicol (EC);</li>\n      <li>Almycetin (PY);</li>\n      <li>Amphen (ET);</li>\n      <li>Anpechlor (PH);</li>\n      <li>Apiclox (BD);</li>\n      <li>Arifenicol (BR);</li>\n      <li>Armisetin (TR);</li>\n      <li>Beaphenicol (SG);</li>\n      <li>Biophenicol (IN);</li>\n      <li>Brocil (MX);</li>\n      <li>C-Phenicol (PH);</li>\n      <li>Cebenicol (VN);</li>\n      <li>Chemicetina (IT);</li>\n      <li>Chemycetin (ES);</li>\n      <li>Chloram-P (TH);</li>\n      <li>Chloramex (ID, QA, SA);</li>\n      <li>Chloranic (GR);</li>\n      <li>Chlorchol (ZA);</li>\n      <li>Chlorcol (ZA);</li>\n      <li>Chlornicol (ZW);</li>\n      <li>Chlornitromycin (BG);</li>\n      <li>Chloromycetin (AR, JP, MX, PH);</li>\n      <li>Chlorphen (ZA);</li>\n      <li>Clorafen (CR, DO, GT, HN, NI, PA, SV);</li>\n      <li>Cloramidina (ID);</li>\n      <li>Colsancetine (ID);</li>\n      <li>Decol (IN);</li>\n      <li>Enclor (SG);</li>\n      <li>Euchlor (VN);</li>\n      <li>Fencol (IN);</li>\n      <li>Fenicol (ID);</li>\n      <li>Gemysetin (TR);</li>\n      <li>Gerafen (PH);</li>\n      <li>Grafacetin (ID);</li>\n      <li>Helocetin (KR);</li>\n      <li>Kalmicetine (IN);</li>\n      <li>Kemicetine (BH, GB, HK, MT, PL, TR);</li>\n      <li>Labchlor (IN);</li>\n      <li>Levomycetin (RU);</li>\n      <li>Levomytsetyn (UA);</li>\n      <li>Medophenicol (TR);</li>\n      <li>Mephicetine (LB);</li>\n      <li>NeoFenicol (BR);</li>\n      <li>Neosechinbi (KR);</li>\n      <li>Ofenicol (PY);</li>\n      <li>Pharmaxin (BD);</li>\n      <li>Quemicitina (AR, BR);</li>\n      <li>Reclor (IN);</li>\n      <li>ShuEr (CN);</li>\n      <li>Sintomicetina (BR);</li>\n      <li>Soluparaxin (SA);</li>\n      <li>Solupraxin (QA);</li>\n      <li>Synthomycin (RU);</li>\n      <li>Type-S (LK);</li>\n      <li>Vixmicina (BR);</li>\n      <li>Xepanicol (ID)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    &lt;800&gt; Hazardous Drugs&mdash;Handling in Healthcare Settings. <i>United States Pharmacopeia and National Formulary </i>(USP 40-NF 35). Rockville, MD: United States Pharmacopeia Convention; 2017:83-102.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ambrose PJ. Clinical pharmacokinetics of chloramphenicol and chloramphenicol succinate. <i>Clin Pharmacokinet</i>. 1984;9(3):222-238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/6375931/pubmed\" target=\"_blank\" id=\"6375931\">6375931</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Atkinson HC, Begg EJ, Darlow BA. Drugs in human milk. Clinical pharmacokinetic considerations. <i>Clin Pharmacokinet</i>. 1988;14(4):217-240.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/3292101/pubmed\" target=\"_blank\" id=\"3292101\">3292101</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Balbi HJ. Chloramphenicol: a review. <i>Pediatr Rev</i>. 2004;25(8):284-288.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/15286274/pubmed\" target=\"_blank\" id=\"15286274\">15286274</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and management of tickborne rickettsial diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis - United States. <i>MMWR Recomm Rep</i>. 2016;65(2):1-44.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/27172113/pubmed\" target=\"_blank\" id=\"27172113\">27172113</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chloramphenicol Sodium Succinate [prescribing information]. Lake Zurich, IL: Fresenius Kabi USA; October 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Coakley JC, Hudson I, Shann F, Connelly JF. A review of therapeutic monitoring of chloramphenicol in patients with Haemophilus influenzae meningitis. <i>J Paediatr Child Health</i>. 1992;28(3):249-253.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/1605978/pubmed\" target=\"_blank\" id=\"1605978\">1605978</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cocke JG Jr, &ldquo;Chloramphenicol Optic Neuritis. Apparent Protective Effects of Very High Daily Doses of Pyridoxine and Cyanocobalamin,&rdquo; <i>Am J Dis Child</i>, 1967, 114(4):424-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/6047242/pubmed\" target=\"_blank\" id=\"6047242\">6047242</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Czeizel AE, Rockenbauer M, S&oslash;rensen HT, Olsen J. A population-based case-control teratologic study of oral chloramphenicol treatment during pregnancy. <i>Eur J Epidemiol</i>. 2000;16(4):323-327.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/10959939/pubmed\" target=\"_blank\" id=\"10959939\">10959939</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Doona M and Walsh JB, &ldquo;Use of Chloramphenicol as Topical Eye Medication: Time to Cry Halt?&rdquo; <i>BMJ</i>, 1995, 310(6989):1217-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/7767184/pubmed\" target=\"_blank\" id=\"7767184\">7767184</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Freundlich M, Cynamon H, Tamer A, et al, &ldquo;Management of Chloramphenicol Intoxication in Infancy by Charcoal Hemoperfusion,&rdquo; <i>J Pediatr</i>, 1983, 103(3):485-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/6886919/pubmed\" target=\"_blank\" id=\"6886919\">6886919</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hammett-Stabler CA and Johns T. Laboratory guidelines for monitoring of antimicrobial drugs. National Academy of Clinical Biochemistry. <i>Clin Chem.</i> 1998;44(5):1129-1140.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/9590397/pubmed\" target=\"_blank\" id=\"9590397\">9590397</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Heinonen OP, Slone D, and Shapiro S. <i>Birth Defects and Drugs in Pregnancy</i>. Littleton, MA: Publishing Sciences Group; 1977.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kimberlin DW, Brady MT, Jackson MA, Long SS, eds; Committee on Infectious Diseases; American Academy of Pediatrics. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kunin CM, Glazko AJ, and Finland M, &ldquo;Persistence of Antibiotics in Blood of Patients With Acute Renal Failure. II. Chloramphenicol and Its Metabolic Products in the Blood of Patients With Severe Renal Failure Disease or Hepatic Cirrhosis,&rdquo; <i>J Clin Invest</i>, 1959, 38(9):1498-508.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/14412753/pubmed\" target=\"_blank\" id=\"14412753\">14412753</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Long S, Pickering L, eds. Bacterial meningitis: antimicrobial therapy. <i>Principles and practice of pediatric infectious diseases.</i> 4th ed. Elsevier Inc; 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Matsuda S. Transfer of antibiotics into maternal milk. <i>Biol Res Pregnancy Perinatol</i>. 1984;5(2):57-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/6743732/pubmed\" target=\"_blank\" id=\"6743732\">6743732</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Messick CR and Pendland SL, &ldquo;<i>In Vitro</i> Activity of Chloramphenicol Alone and in Combination With Vancomycin, Ampicillin, or RP 59500 (Quinupristin/Dalfopristin) Against Vancomycin-Resistant Enterococci,&rdquo; <i>Diagn Microbiol Infect Dis</i>, 1997, 29(3):203-5.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Moffa M and Brook I; Tetracyclines, Glycylcyclines, and Chloramphenicol. In: Bennett JE, Dolin R, and Blaser MJ, eds. <i>Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases</i>. 8th ed. Philadelphia, PA: Elsevier, 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Montoro A, Cao A, Ordoqui E, et al, &ldquo;Contact Sensitivity to Chloramphenicol,&rdquo; <i>J Allergy Clin Immunol</i>, 1995, 95:291.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mulhall A, de Louvois J, Hurley R. Efficacy of chloramphenicol in the treatment of neonatal and infantile meningitis: a study of 70 cases. <i>Lancet</i>. 1983;1(8319):284-287.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/6130304/pubmed\" target=\"_blank\" id=\"6130304\">6130304</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nahata MC and Powell DA, &ldquo;Bioavailability and Clearance of Chloramphenicol After Intravenous Chloramphenicol Succinate,&rdquo; <i>Clin Pharmacol Ther</i>, 1981, 30(3):368-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/7273601/pubmed\" target=\"_blank\" id=\"7273601\">7273601</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Plomp TA, Thiery M, and Maes RA, &quot;The Passage of Thiamphenicol and Chloramphenicol Into Human Milk After Single and Repeated Oral Administration,&quot; <i>Vet Hum Toxicol</i>, 1983, 25(3):167-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/6868331/pubmed\" target=\"_blank\" id=\"6868331\">6868331</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Powell DA, Nahata MC. Chloramphenicol: new perspectives on an old drug. <i>Drug Intell Clin Pharm</i>. 1982;16(4):295-300.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/040026/pubmed\" target=\"_blank\" id=\"040026\">040026</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Ramilo O, Kinane BT, and McCracken GH Jr, &ldquo;Chloramphenicol Neurotoxicity,&rdquo; <i>Pediatr Infect Dis J</i>, 1988, 7(5):358-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/3380586/pubmed\" target=\"_blank\" id=\"3380586\">3380586</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Smilack JD, Wilson WR, and Cockerill FR 3d, &ldquo;Tetracyclines, Chloramphenicol, Erythromycin, Clindamycin, and Metronidazole,&rdquo; <i>Mayo Clin Proc</i>, 1991, 66(12):1270-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/1749296/pubmed\" target=\"_blank\" id=\"1749296\">1749296</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Wispelwey B, and Scheld M, &ldquo;Bacterial Meningitis: Recent Advances in Pathophysiology and Treatment,&rdquo; <i>Ann Intern Med</i>, 1990, 112(8):610-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/2183667/pubmed\" target=\"_blank\" id=\"2183667\">2183667</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Vozeh S, Schmidlin O, and Taeschner W, &ldquo;Pharmacokinetic Drug Data,&rdquo; <i>Clin Pharmacokinet</i>, 1988, 15(4):254-82.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/3359738/pubmed\" target=\"_blank\" id=\"3359738\">3359738</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    World Health Organization (WHO). Breastfeeding and maternal medication, recommendations for drugs in the Eleventh WHO Model List of Essential Drugs. 2002. Available at www.who.int/maternal_child_adolescent/documents/55732/en/</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yoshikawa TT, &ldquo;Antimicrobial Therapy for the Elderly Patient,&rdquo; <i>J Am Geriatr Soc</i>, 1990, 38(12):1353-72.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/2254575/pubmed\" target=\"_blank\" id=\"2254575\">2254575</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Yunis AA, &ldquo;Chloramphenicol: Relation of Structure to Activity and Toxicity,&rdquo; <i>Annu Rev Pharmacol Toxicol</i>, 1988, 28:83-100.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/chloramphenicol-drug-information/abstract-text/3289495/pubmed\" target=\"_blank\" id=\"3289495\">3289495</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 9241 Version 187.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708673\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F149436\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F149484\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F149440\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F149462\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F149441\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F149442\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F149443\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F149410\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F149395\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F149415\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49130927\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F149414\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F149491\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F149402\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F149418\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F149399\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F149480\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F149404\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F50102719\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F149420\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F149421\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F149422\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F149408\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Reference Range\" href=\"#F149411\" class=\"outlineLink\">Reference Range</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F149398\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F149417\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323057\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F2869368\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/9241|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=chloramphenicol-patient-drug-information\" class=\"drug drug_patient\">Chloramphenicol: Patient drug information</a></li><li><a href=\"topic.htm?path=chloramphenicol-pediatric-drug-information\" class=\"drug drug_pediatric\">Chloramphenicol: Pediatric drug information</a></li></ul></div></div>","javascript":null}